Frankfurt
30.07.25 | 08:08
0,044 Euro
-2,21 % -0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.07. | KLARIA PHARMA HOLDING AB: Klaria stengthens patent portfolio of sumatriptan alginate film with new filing | 3 | Cision News | ||
| 18.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.06.2025 | 386 | Xetra Newsboard | Das Instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 18.06.2025 The instrument FCC ES0122060314 FOMENT.CON.CONTR.INH.EO 1 EQUITY is traded ex capital... ► Artikel lesen | |
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 21.05. | KLARIA PHARMA HOLDING AB: Klaria Interim Report | 4 | Cision News | ||
| 30.04. | KLARIA PHARMA HOLDING AB: Klaria Annual Report 2024 | 3 | Cision News | ||
| 28.02. | Klaria Pharma Holding AB: Klaria Year-End Report 2024 | 175 | GlobeNewswire (Europe) | Klaria year-end report 1 Jan - 31 Dec 2024
Summary of the reportFourth quarter of 2024
The group in total
- Net sales 1.1 MSEK (1.3 MSEK)
- Other income 0.0 MSEK (0.3 MSEK)
- R&D expenses for... ► Artikel lesen | |
| 10.01. | Klaria Pharma Holding AB: Klaria signs license agreement for Sumatriptan Alginate film in Europe with CNX Therapeutics | 268 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has signed a license agreement for Sumatriptan Alginate Film (the "Product"), a pharmaceutical product based on... ► Artikel lesen | |
| 21.11.24 | Klaria Pharma Holding AB: Klaria Interim Report Q3 2024 | 122 | GlobeNewswire (Europe) | Klaria Interim Report Q3 2024
1 July - 30 September 2024
Third quarter of 2024
The group in total
- Net sales 0.0 MSEK (0.6 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the... ► Artikel lesen | |
| 22.08.24 | Klaria Pharma Holding AB: Klaria Interim Report Q2 2024 | 119 | GlobeNewswire (Europe) | Summary of Interim Report
First quarter of 2024
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.3 MSEK)
- R&D expenses for the quarter amounted to 0.5 MSEK (7.0... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 40,320 | -0,68 % | Bristol Myers Squibb beruft neuen Chief Medical Officer | Der US-Pharmakonzern Bristol Myers Squibb hat am Freitag bekanntgegeben, dass Cristian Massacesi zum 1. August 2025 die Rolle des Executive Vice President, Chief Medical Officer und Leiters der weltweiten... ► Artikel lesen | |
| DERMAPHARM | 34,200 | -2,98 % | Kaum Impulse für die Dermapharm-Aktie (35,20 €) | Die Wertschätzung für den Anteilsschein von Dermapharm hat sich am Aktienmarkt heute kaum geändert. Zuletzt zahlten Investoren für die Aktie 35,20 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung... ► Artikel lesen | |
| SYNBIOTIC | 3,055 | +1,16 % | EQS-News: SYNBIOTIC SE: Verdreifachung des Umsatzes bis 2027 erwartet: Fokussierung auf Wachstumsmärkte für Medizinalcannabis und Industriehanf unterstreicht einen positiven Ausblick für SYNBIOTIC | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Strategische Unternehmensentscheidung/Umsatzentwicklung
Verdreifachung des Umsatzes bis 2027 erwartet: Fokussierung auf Wachstumsmärkte... ► Artikel lesen | |
| INCYTE | 68,08 | +1,61 % | Incyte Q2 Results Top Estimates | WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) on Tuesday reported net income of $405.0 million or $2.04 per share for the second quarter, compared to a net loss of $444.60 million or $2.04 per... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
| GREEN THUMB INDUSTRIES | 5,300 | +3,72 % | Green Thumb Industries Reports First Quarter 2025 Results | CHICAGO and VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| INDIVA | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.06.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.06.2025.ISIN NameCA45580J1012 INDIVA... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,630 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces the Passing of Chief Financial Officer Gary Fung | Toronto, Ontario--(Newsfile Corp. - July 25, 2025) - It is with profound sadness that Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company") announces the passing... ► Artikel lesen | |
| CSPC PHARMA | 1,119 | +4,04 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited | License agreement supports Madrigal's pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra (resmetirom) Combining Rezdiffra with... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 35,600 | -3,78 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| OPKO HEALTH | 1,191 | +1,55 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| PSYCHED WELLNESS | 0,010 | -20,83 % | Psyched Wellness Ltd.: Psyched Wellness Provides Comprehensive Investor Update | Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,522 | +3,68 % | SELLAS Life Sciences Group, Inc.: SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study | The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30... ► Artikel lesen | |
| COSMO PHARMACEUTICALS | 65,00 | -1,52 % | Cosmo Pharmaceuticals N.V.: Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology | Ad hoc announcement pursuant to Art. 53 LR EBITDA guidance raised by €4.5M as Cosmo executes on its Vision 2030 strategy; H1 Recurring Revenues from GI Genius up 128%, Winlevi® up 23%; Investors... ► Artikel lesen | |
| SWEET EARTH | 0,324 | -100,00 % | CSE Bulletin: 2025 - 0621 - Halted for Fundamental Change - Sweet Earth Holdings Corporation (SE) | Toronto, Ontario--(Newsfile Corp. - Le 19 juin/June 2025) - Trading in the shares of Sweet Earth Holdings Corporation (SE) will remain halted pending receipt and review of acceptable documentation... ► Artikel lesen |
Das Unternehmen KLARIA PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,044 Euro und damit -2,21 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.